Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

By B. Scirica, E. Braunwald, I. Raz, M. Cavender, D. A. Morrow, P. Jarolím, J. Udell, Ofri Mosenzon, K. Im, A. Umez-Eronini and 8 more. Circulation, 2015

623 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/fc1d069653a4268ad6491affffd1473d80ce6206

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. W. Paulus
2. Gerasimos Filippatos
3. F. Cosentino
4. C. Tschöpe
5. Barry A. Borlaug

In Endocrinology, Diabetes and Metabolism

1. John B. Buse
2. E. Ferrannini
3. M. Nauck
4. Silvio E. Inzucchi
5. F. Cosentino
6. V. Basevi

In Pulmonary and Respiratory Medicine

1. W. Paulus

Citations in the corpus

• Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015, background): “DPP-4 inhibitors and heart failure and the issues concerning SGLT2 inhibitors and renal status should be taken into consideration [29].”
• Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018, methodology): “terminal pro B-type natriuretic peptide (NT-proBNP) (74).”